Navigation Links
Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
Date:4/17/2008

Berlin, Germany: The first study to investigate the effects of chemotherapy on metastatic breast cancer in women with the BRCA1 or BRCA2 gene mutation has shown that standard chemotherapy works better in these patients than in women without the BRCA1/2 mutation.

The authors of a study presented today (Thursday) at the 6th European Breast Cancer Conference (EBCC-6) in Berlin found that women with BRCA2-associated breast cancer had a significantly higher response rate, a longer time without the disease progressing, and a longer overall survival when treated with anthracycline-based regimens than did women with sporadic breast cancers that were not associated with BRCA1/2.

Women with BRCA1-associated breast cancer also did better than women with sporadic breast cancer, but the rates were not statistically significant.

Researchers at the Daniel den Hoed Cancer Centre/Erasmus Medical Centre (Rotterdam, The Netherlands) conducted the study. They matched 112 women with BRCA1-associated metastatic cancer and 29 women with BRCA2-associated metastatic cancer with 141 women with sporadic breast cancers. The women had been treated with anthracycline-based or taxane-based regimens, CMF (cyclophosphamide, methotrexate and fluorouracil 5FU) or other chemotherapy regimens.

BRCA2 women had a higher response rate to chemotherapy (89% versus 50%), a longer progression-free survival (nearly a third better) and a longer overall survival (47% better) than did women with sporadic cancers. When the researchers looked more closely at the type of chemotherapy the women had received, they found that the improved progression-free survival mainly occurred in patients on anthracyclines and disappeared for those treated with CMF.

The lead author of the study, Dr Mieke Kriege, an epidemiologist and project researcher at the Rotterdam Family Cancer Clinic, said: It is difficult to make firm conclusions about response to different treatments from ou
'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. Minimum information standards -- all for 1 and 1 for all
2. CO2 emissions could violate EPA ocean-quality standards within decades
3. Positron emission tomography superior to standard evaluation tools in measuring treatment response
4. NIST, Army researchers pave the way for anthrax spore standards
5. UC health news: molecular pathway may predict chemotherapy effectiveness
6. A search for protection against chemotherapy cardiotoxicity
7. Rain forest protection works in Peru
8. MIT works toward safer gene therapy
9. IdentiPHI Re Launches SAFmodule Software to Secure Novell(R) Networks
10. IdentiPHI Re Launches SAFmodule Software to Secure Novell(R) Networks
11. Alternative food networks connect ethical producers and consumers and can lead to healthier eating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... Matthew Levy, Ph.D., assistant professor of biochemistry at ... has been awarded more than $700,000 by Stand ... research. Dr. Levy,s work will focus on creating ... eliminating or significantly reducing serious or unpleasant side ... of 13 young scientists nationwide selected to receive ...
(Date:12/6/2009)... N.Y./Los Angeles, Calif.: Stand Up To Cancer (SU2C) ... support high-risk/high-reward cancer research conducted by 13 young scientists. ... total of up to $750,000 as part of SU2C,s ... of cancer research leaders. , "We asked our best ... zones and strive to make big differences with bold ...
(Date:12/6/2009)... Just three months after the Euro 5 Norm for ... models, researchers at the Technische Universitaet Muenchen (TUM) have ... the more stringent Euro 6 emissions standard. A research ... of Internal Combustion Engines has succeeded in reducing the ... TUM engineers have also developed a probe that allows ...
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6Munich lab demonstrates diesel truck engine with barely measurable emissions 2Munich lab demonstrates diesel truck engine with barely measurable emissions 3Scans Shed New Light on Concussions 55629 1Scans Shed New Light on Concussions 55629 2Solution to PREVENT Novel H1N1 28Swine Flu 29 From Closing Down Schools 21 55627 1Solution to PREVENT Novel H1N1 28Swine Flu 29 From Closing Down Schools 21 55627 2Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant 28Oral 29 At The European Society Of Cardiology Congres 55625 1Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant 28Oral 29 At The European Society Of Cardiology Congres 55625 2Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant 28Oral 29 At The European Society Of Cardiology Congres 55625 3
... you make for your child could well be a ring ... help the plant produce cyanide to protect itself against ... clover. Other clover plants that do not make cyanide are ... poison, er, clover, ecology and geography play important roles. ...
... pretzel factory production line, with conveyer belts carrying the dough, formed ... , Now imagine what would happen if pretzel dough started to ... misshapen, and sticking fast to the dough of the other fully ... could no longer be conveyed into the oven, the backup of ...
... p.m. , The New York Academy of Sciences, 7 ... York, NY 10007 , The Malaria Research Institute at ... The New York Academy of Sciences present Progress Against ... highlight the latest research developments in the fight to ...
Other Biology News:Genetic differences in clover make one type toxic 2Genetic differences in clover make one type toxic 3Botched production of insulin molecule may lead to diabetes 2Botched production of insulin molecule may lead to diabetes 3Botched production of insulin molecule may lead to diabetes 4Progress Against Malaria: Developments on the Horizon 2
(Date:12/7/2009)... discover and develop systems biology-driven therapeutics to include small ... , ... Cambridge, ... announced today that it has acquired Hermes Biosciences, Inc. ... California. Hermes specializes in targeted drug delivery technologies ...
(Date:12/7/2009)... received ANVISA approval to market the TriPollar Technology- the most advanced ... TriPollar anti-aging products have been clinically proven the world over ... is completely painless and non-invasive and patients enjoy visible results from ... undergoing a series of treatments. , ... ...
(Date:12/7/2009)... -- WuXi PharmaTech (NYSE: WX ... research and,development outsourcing company with operations in ... has purchased a Labcyte POD(TM) 810 plate ... handler for its work in high-,throughput screening ... the,growing number of pharmaceutical companies worldwide that ...
(Date:12/6/2009)... 6 A challenge donation from the Bezos ... fundraising total to more than $7 million for Fred ... portion of the live auction during which guests raise ... $6.4 million to be directed toward the Hutchinson Center,s ... cancer. ,, The black-tie Gala took place Dec. ...
Breaking Biology Technology:Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 234th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 234th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 3
... MOUNTAIN VIEW, Calif., May 13 Based on ... & Sullivan recognizes Precision Biosciences with the 2009 ... Innovation of the Year. The company,s radical Directed ... and modify regions of a cell,s genome with ...
... 12 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) ... on Tuesday, May 19, 2009 at 11:30 a.m. ... Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will ... be webcast, and a recording will be made available following ...
... 12 Masimo Corporation (Nasdaq: MASI ), the ... oximetry, today announced that its management is scheduled to present ... Boston, Massachusetts, on Tuesday, May 19, 2009, at 2:35 p.m. ... available on the Masimo website at www.masimo.com . ...
Other Biology Technology:Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market 2Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market 3Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market 4Masimo to Present at the Deutsche Bank 34th Annual Health Care Conference 2